CG-T1

Next-Generation Peptide-Based Therapy for Dry Eye Disease (DED) CG-T1 is a novel topical peptide therapeutic candidate under preclinical development for the treatment of dry eye disease (DED). Unlike conventional cyclosporine-based eye drops, CG-T1 is designed to offer rapid onset of action, a milder and more tolerable profile, and a fundamentally distinct mechanism of action. CG-T1 promotes tear secretion and ocular surface repair by stimulating the lacrimal gland, goblet cells, and corneal epithelial regeneration. Mechanistically, it enhances mucin production (MUC5AC) through P2Y2 activation, protects corneal nerves, and inhibits inflammatory mediators such as NF-κB, IL-6, and TNF-α. It also reduces reactive oxygen species (ROS) and stabilizes the epithelial barrier, thereby addressing multiple DED pathologies in parallel.